2026-09-25 22:09:04 UTC#371304duplicateconfirmednews
US FDA approves AbbVie's Juvmo (tavapadon) for adult Parkinson's disease
reutersimportance 0.30trust 0.90AbbVie Inc. +0.50U.S. Food and Drug Administration 0tavapadon +0.60+1 entities
AbbVie (ABBV) stock news
AbbVie (ABBV) stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-09-25 22:04:09 UTC#371301duplicateconfirmednews
US FDA approves AbbVie Parkinson's disease treatment
2026-09-25 22:00:11 UTC#371294newconfirmednews
US FDA approves AbbVie's new drug for adult Parkinson's disease treatment
2026-09-25 09:30:00 UTC#367652newconfirmedanalysis
Protagonist Therapeutics' oral peptide platform gains traction, challenging AbbVie's market position
dow_jonesimportance 0.40trust 0.80Protagonist Therapeutics, Inc. +0.60Johnson & Johnson +0.40AbbVie Inc. -0.30+1 entities
2026-09-24 23:17:00 UTC#366042duplicateconfirmedpress release
REGENXBIO reports 3-year durability data for surabgene lomparvovec in diabetic retinopathy
yahooimportance 0.40trust 0.90REGENXBIO Inc. +0.60surabgene lomparvovec +0.60ALTITUDE +0.50+2 entities
2026-09-24 11:03:15 UTC#361745newconfirmednews
AbbVie's Epkinly Receives Health Canada Approval for Adult Follicular Lymphoma Treatment
2026-09-24 11:01:00 UTC#361781duplicateconfirmedpress release
AbbVie receives Health Canada approval for Epkinly in adult follicular lymphoma treatment
2026-09-23 18:42:14 UTC#357829updateconfirmednews
Iambic Therapeutics, Backed by Nvidia, Announces AbbVie Research Partnership Ahead of IPO
yahooimportance 0.50trust 0.70Iambic Therapeutics, Inc. +0.40NVIDIA Corporation +0.30AbbVie Inc. +0.40+1 entities
2026-09-22 07:15:23 UTC#347026newconfirmednews
AbbVie discloses $600M China asset payment, faces House inquiry on clinical trials, and invests in ADARx IPO
tradingviewimportance 0.60trust 0.60AbbVie Inc. -0.20ADARx Pharmaceuticals, Inc. +0.30Iambic Therapeutics +0.30+1 entities
2026-09-22 06:30:19 UTC#346807newconfirmednews
AbbVie's Rinvoq receives European Commission approval for pediatric arthritis treatment
2026-09-21 12:09:50 UTC#342197newconfirmednews
AbbVie enters multi-year AI drug discovery partnership with Iambic Therapeutics
seeking alphaimportance 0.40trust 0.70AbbVie Inc. +0.30Iambic Therapeutics +0.30Artificial Intelligence +0.20
2026-09-21 11:28:15 UTC#341888newconfirmednews
AbbVie acquires Apogee Therapeutics for immunology pipeline; expects Q4 SKYRIZI Crohn's approval
tradingviewimportance 0.50trust 0.60AbbVie Inc. +0.50Apogee Therapeutics, Inc. +0.60SKYRIZI +0.40+2 entities
2026-09-21 11:17:00 UTC#341821updateconfirmednews
ADARx Pharmaceuticals sets IPO price range at $15-$17 per share for 21.9 million share offering
2026-09-19 03:18:37 UTC#336330duplicateconfirmednews
AbbVie shares additional real-world and pediatric safety data for VRAYLAR at Psych Congress 2026
2026-09-18 12:30:00 UTC#333317newconfirmedpress release
AbbVie presents new real-world data for VRAYLAR in MDD and bipolar I depression at Psych Congress 2026
2026-09-17 12:30:00 UTC#327416updateconfirmednews
AbbVie to present Phase 3 CERVINO etentamig data and broader myeloma portfolio at 2026 IMS meeting
yahooimportance 0.40trust 0.90AbbVie Inc. +0.50International Myeloma Society 0etentamig +0.50+2 entities
2026-09-17 12:30:00 UTC#327379newconfirmedpress release
AbbVie's Phase 3 CERVINO trial for etentamig meets primary endpoints in relapsed/refractory multiple myeloma
pr newswireimportance 0.40trust 0.90AbbVie Inc. +0.50International Myeloma Society 0etentamig +0.50+1 entities
2026-09-17 12:00:00 UTC#327161newconfirmednews
Allergan Aesthetics presents clinical data on skincare and DiamondGlow for GLP-1 weight loss medication users
yahooimportance 0.40trust 0.90Allergan Aesthetics +0.40AbbVie Inc. +0.30DiamondGlow +0.40+2 entities
2026-09-15 15:59:27 UTC#315296duplicateconfirmedanalysis
AbbVie reaffirms growth strategy in immunology, neuroscience, and oncology via pipeline and Apogee acquisition
2026-09-15 15:07:21 UTC#314891updateconfirmedanalysis